Stock Price
1.69
Daily Change
5.63%
Yearly
-62.02%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Applied Genetic Technologies 1.69 0.09 5.63% -62.02%
Alimera Sciences 4.36 0.15 3.61% -39.92%
Avrobio Inc 1.91 0.05 2.69% -87.19%
Biogen 222.31 -2.38 -1.06% -18.17%
Bluebird Bio 7.83 0.12 1.56% -83.00%
Celldex Therapeutics 29.51 0.66 2.29% 46.74%
CTI Biopharma 2.04 -0.13 -5.99% -38.74%
Gilead Sciences 68.84 0.27 0.39% 3.21%
Intercept Pharmaceuticals 15.38 -0.23 -1.47% -59.26%
Insmed 21.69 -0.61 -2.74% -48.66%
Life Technologies 5.93 -0.12 -1.98% 50.51%
Iveric bio Inc. 12.90 0.21 1.65% 125.52%
Ultragenyx Pharmaceutical 69.07 1.11 1.63% -49.27%
Regeneron Pharmaceuticals 603.19 -18.29 -2.94% 10.86%
Rigel Pharmaceuticals 2.43 0.01 0.41% -31.36%
Roche Holding 347.85 1.65 0.48% 7.71%
Sanofi 51.40 0.56 1.10% 3.57%

Indexes Price Day Year
NASDAQ 13539 -315.83 -2.28% -0.64%
US2000 2016 -17.18 -0.84% -6.21%

Applied Genetic Technologies
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is in the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM), and optogenetics. The Company has approximately one preclinical program in otology and three preclinical programs targeting central nervous system disorders (CN), including adrenoleukodystrophy (ALD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company's optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.